Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Pierre Saintingy"'
Publikováno v:
PLOS Global Public Health, Vol 3, Iss 9, p e0002366 (2023)
This article will elaborate how oncology care and research was adapted during the COVID pandemic in the Metropole of Lyon (France), including the lasting innovations that came out of the crisis. The research method involved 22 semi-structured qualita
Externí odkaz:
https://doaj.org/article/c0f008eda92a4999a6553796216dbc91
Autor:
Clive Morris, Solène Marteau, Camille Leonce, Lionel Falchero, Pierre Saintingy, Gilles Clapisson, Maurice Pérol, Virginie Avrillon, Pierre Fournel, Sandra Ortiz-Cuaran, Emma Green, Luc Odier, Aurélie Swalduz, Séverine Martinez
Publikováno v:
Cancer Research. 78:937-937
Background: In EGFR-mutant non-small cell lung cancer (NSCLC), progression disease (PD) under 1st-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) is driven by the EGFR T790M mutation in about 50% of cases. This mutation is targeted with osimer
Abstract 1841: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas
Autor:
Pierre Saintingy, Solène Marteau, Anne Pradines, Karen Howarth, Emma Green, Aurélie Swalduz, Gilles Clapisson, Jean-Yves Blay, Etienne Brain, Etienne Giroux Leprieur, Frank de Kievit, C. Raynaud, Virginie Avrillon, Virginie Westeel, Isabelle Monnet, Xavier Quantin, Nathalie Hoog-Labouret, Julien Mazieres, Claire Tissot, Séverine Martinez, Radj Gervais, Clive Morris, Celine Mahier, Y. Loriot, Washington René Chumbi Flores, Sandra Ortiz-Cuaran, Séverine Neymarc, Nathalie Girerd-Chambaz, Maurice Pérol, Christelle Clément Duchene
Publikováno v:
Cancer Research. 78:1841-1841
Background: BRAF mutations occur in 2 to 3% of patients (pts) with non-small cell lung cancer (NSCLC). In these pts vemurafenib, a selective oral BRAF inhibitor is associated with a response rate (RR) of 42%, rising to 64% for combination treatment w